Skyline Biosciences   Report issue

For profit Phase 1 Phase 2
Founded: Northbrook IL United States (2018)

Organization Overview

First Clinical Trial
2019
NCT03939364
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Skyline Biosciences | Skyline Therapeutics (US) Inc.